OSE Immunotherapeutics SA
PAR:OSE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Unifi Inc
NYSE:UFI
|
US |
|
Sichuan Chuanhuan Technology Co Ltd
SZSE:300547
|
CN |
OSE Immunotherapeutics SA
Total Liabilities
OSE Immunotherapeutics SA
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
OSE Immunotherapeutics SA
PAR:OSE
|
Total Liabilities
€53.6m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
9%
|
CAGR 10-Years
35%
|
|
|
Valneva SE
PAR:VLA
|
Total Liabilities
€292.7m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
8%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Total Liabilities
€181.6m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
29%
|
|
|
Inventiva SA
PAR:IVA
|
Total Liabilities
€187.9m
|
CAGR 3-Years
39%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Total Liabilities
$64.6m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
12%
|
|
|
Abivax SA
PAR:ABVX
|
Total Liabilities
€164.6m
|
CAGR 3-Years
34%
|
CAGR 5-Years
20%
|
CAGR 10-Years
36%
|
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
See Also
What is OSE Immunotherapeutics SA's Total Liabilities?
Total Liabilities
53.6m
EUR
Based on the financial report for Jun 30, 2025, OSE Immunotherapeutics SA's Total Liabilities amounts to 53.6m EUR.
What is OSE Immunotherapeutics SA's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
35%
Over the last year, the Total Liabilities growth was -9%. The average annual Total Liabilities growth rates for OSE Immunotherapeutics SA have been -1% over the past three years , 9% over the past five years , and 35% over the past ten years .
